# A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

> **NCT04442022** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 501 (estimated)

## Conditions studied

- Relapsed/Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Selinexor (combination therapy)
- **DRUG:** Selinexor (combination therapy)
- **DRUG:** Selinexor (combination therapy)
- **DRUG:** Placebo matching for Selinexor (combination therapy)
- **DRUG:** Rituximab (combination therapy)
- **DRUG:** Rituximab (combination therapy)
- **DRUG:** Gemcitabine (combination therapy)
- **DRUG:** Dexamethasone (combination therapy)
- **DRUG:** Cisplatin (combination therapy)
- **DRUG:** Selinexor (continuous therapy)
- **DRUG:** Placebo matching for Selinexor (continuous therapy)

## Key facts

- **NCT ID:** NCT04442022
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-03
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 501 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442022, "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04442022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*